We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+49.88%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$5.33B
AUM Growth
+$851M
Cap. Flow
+$41.1M
Cap. Flow %
0.77%
Top 10 Hldgs %
79.43%
Holding
93
New
17
Increased
12
Reduced
17
Closed
13

Top Buys

Rank Stock Value
1
MBLY
Mobileye N.V.
MBLY
+$15.6M
2
V icon
Visa
V
+$13.6M
3
JPM icon
JPMorgan Chase
JPM
+$13M
4
CELG
Celgene Corp
CELG
+$11.6M
5
YUM icon
Yum! Brands
YUM
+$10.9M

Top Sells

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$17.2M
2
BAC icon
Bank of America
BAC
+$15.6M
3
LNKD
LinkedIn Corporation
LNKD
+$5.67M
4
KITE
Kite Pharma, Inc.
KITE
+$2.82M
5
NKTR icon
Nektar Therapeutics
NKTR
+$2.74M

Sector Composition

Rank Sector Weight
1 Consumer Staples 40.39%
2 Healthcare 20%
3 Consumer Discretionary 13.89%
4 Financials 1.45%
5 Technology 0.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QCOM icon
51
Qualcomm
QCOM
$169B
$8.22M 0.15%
+164,500
New +$8.78M
CCXI
52
DELISTED
ChemoCentryx, Inc.
CCXI
$7.29M 0.14%
900,000
– –
CLLS
53
Cellectis
CLLS
$289M
$6.52M 0.12%
210,000
+85,000
+68% +$2.58M
AGIO icon
54
CALL
Agios Pharmaceuticals
AGIO
$2.09B
$6.49M 0.12%
+100,000
New +$6.56M
RXDX
55
DELISTED
Ignyta, Inc.
RXDX
$6.37M 0.12%
475,000
– –
IONS icon
56
CALL
Ionis Pharmaceuticals
IONS
$9.09B
$6.19M 0.12%
100,000
– –
MCRB icon
57
Seres Therapeutics
MCRB
$45.8M
$6.14M 0.12%
8,750
-1,250
-13% -$822K
CLDX icon
58
Celldex Therapeutics
CLDX
$2.81B
$5.88M 0.11%
25,000
– –
INCY icon
59
CALL
Incyte
INCY
$25.6B
$5.42M 0.1%
+50,000
New +$5.58M
LCTX icon
60
Lineage Cell Therapeutics
LCTX
$262M
$5.26M 0.1%
1,588,475
– –
DAL icon
61
Delta Air Lines
DAL
$57.6B
$5.07M 0.1%
+100,000
New +$4.94M
JMEI
62
DELISTED
Jumei International Holding Limited American depositary shares, each representing ten Class A ordina
JMEI
$4.53M 0.09%
50,000
– –
IBRX icon
63
ImmunityBio
IBRX
$7.33B
$3.9M 0.07%
225,000
+50,000
+29% +$742K
SRPT icon
64
CALL
Sarepta Therapeutics
SRPT
$1.6B
$3.86M 0.07%
+100,000
New +$3.24M
HAPN
65
CALL
Happen Inc
HAPN
$2.16B
$3.59M 0.07%
65,000
– –
BLUE
66
CALL
DELISTED
bluebird bio
BLUE
$3.21M 0.06%
3,860
– –
RGNX icon
67
Regenxbio
RGNX
$617M
$2.66M 0.05%
160,000
+42,600
+36% +$846K
IRWD icon
68
Ironwood Pharmaceuticals
IRWD
$614M
$2.51M 0.05%
258,954
– –
AGEN
69
Agenus
AGEN
$279M
$2.5M 0.05%
28,023
– –
DMTX
70
DELISTED
Dimension Therapeutics, Inc
DMTX
$1.97M 0.04%
+175,000
New +$2.21M
PARN
71
DELISTED
Parnell Pharmaceuticals Holdings Ltd
PARN
$1.94M 0.04%
500,000
– –
SPNC
72
DELISTED
Spectranetics Corp
SPNC
$1.51M 0.03%
100,000
– –
ARRY
73
CALL
DELISTED
Array Biopharma Inc
ARRY
$1.27M 0.02%
300,000
– –
XOMA
74
CALL
DELISTED
Xoma
XOMA
$532K 0.01%
20,000
– –
CERE
75
DELISTED
CERES, INC. COMMON STOCK NEW
CERE
$338K 0.01%
1,024,020
– –
1 2
3
4

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q4 2015 Portfolio in Review

As of Q4 2015, Artal Group held 93 positions worth $5.33B, up 19% from $4.48B the previous quarter. Its ten largest holdings account for 79% of the portfolio.

Artal Group's Q4 2015 filing shows 17 new, 12 increased, 17 reduced and 13 closed positions. Its largest new stake was Mobileye N.V.: 350,000 shares worth $14.8M. The largest sale was BioMarin Pharmaceuticals, an estimated $17.2M.

By sector, the portfolio is most concentrated in Consumer Staples at 40% of assets, down from 46% a quarter earlier, followed by Healthcare and Consumer Discretionary.

  • Artal Group's largest Q4 2015 buy was Mobileye N.V.: 350,000 shares worth $14.8M.
  • Artal Group added most to Yum! Brands in Q4 2015, an estimated $10.9M increase.
  • Artal Group's biggest Q4 2015 reduction was BioMarin Pharmaceuticals, cutting an estimated $17.2M.
  • Artal Group fully exited Bank of America in Q4 2015, selling an estimated $15.6M.
  • Artal Group's ten largest holdings make up 79% of its $5.33B portfolio in Q4 2015.
  • Artal Group opened 17 new positions and closed 13 in Q4 2015.
  • Artal Group's portfolio value rose 19% quarter-over-quarter to $5.33B.

Based on Artal Group's 13F filing for Q4 2015, filed 12 Feb 2016.